Peritoneal carcinomatosis of gastrointestinal origin: Natural history and treatment options

Expert Opinion on Investigational Drugs

Volumn 18, Issue 7, 2009, Pages 913-919

  Davies, Janine Marie ^a   O'Neil, Bert ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Peritoneal carcinomatosis; Pseudomyxoma peritonei; Systemic therapy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PACLITAXEL;

ABDOMINAL PAIN; ACIDOSIS; ANASTOMOSIS LEAKAGE; ANEMIA; APPENDIX TUMOR; BLEEDING; CANCER CHEMOTHERAPY; CARCINOMATOUS PERITONITIS; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; DRUG MEGADOSE; GASTROINTESTINAL TRACT; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; ILEUS; LIVER TOXICITY; LYMPHOCYTOPENIA; PERITONEUM PSEUDOMYXOMA; PROGNOSIS; REVIEW; SIDE EFFECT; STOMACH PERFORATION; SURVIVAL TIME; SYSTEMIC THERAPY; THROMBOCYTOPENIA;

ANIMALS; CARCINOMA; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; GASTROINTESTINAL NEOPLASMS; HUMANS; PERITONEAL NEOPLASMS;

EID: 67650465882     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780902939151     Document Type: Review

References (27)

1. Chu DZJ, Lang NP, Thompson C, et al. Peritioneal carcinomatosis in nongynecologic malignancy: a prospective study of prognostic factors. Cancer 1989;63:364-7
2. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88:358-63
3. Glehen O, Osinsky D, Beaujard AC, et al. Natural history of peritoneal carcinomatosis from nongynecologic malignancies. Surg Oncol Clin N Am 2003;12:729-39, xiii
4. Bartlett DL, Buell JF, Libutti SK, et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer 1998;83:1251-61
5. Speyer JL, Collins JM, Dedrick RL, et al. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res 1980;40:567-72
6. Stewart JH, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions. Ann Surg Oncol 2005;12:765-77
7. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43
8. Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008;15:2426-32
9. Levine EA, Stewart JHT, Russell GB, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. J Am Coll Surg 2007;204:943-53; discussion 953-45
10. Ceelen WP, Peeters M, Houtmeyers P, et al. Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis. Ann Surg Oncol 2008;15:535-41
11. van Leeuwen BL, Graf W, Pahlman L, et al. Swedish experience with peritonectomy and HIPEC. HIPEC in peritoneal carcinomatosis. Ann Surg Oncol 2008;15:745-53
12. McQuellon RP, Danhauer SC, Russell GB, et al. Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2007;14:1105-13
13. Gusani NJ, Cho SW, Colovos C, et al. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Ann Surg Oncol 2008;15:754-63
14. Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737-43
15. Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009;27:681-5
16. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004;22:3284-92
17. Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol 2007;14:128-33
18. Pingpank J. Peritoneal carcinomatosis. In: Devita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott Williams & Wilkins, 2005. p. 2237-46
19. Ronnett B, Zahn C, Kurman R, et al. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to 'Pseudomyxoma Peritonei'. Am J Surg Path 1995;19:1390-408
20. Yan TD, Black D, Savady R, et al. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 2007;14:484-92
21. Baratti D, Kusamura S, Nonaka D, et al. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 2008;15:526-34
22. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999;6:727-31
23. Farquharson AL, Pranesh N, Witham G, et al. A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable Pseudomyxoma peritonei. Br J Cancer 2008;99:591-6
24. Stewart JH, Shen P, Russell G, et al. A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers. Ann Surg Oncol 2008;15:2137-45
25. Folprecht G, Lutz MP, Rougier P, et al. Effect of systemic chemotherapy (CTx) in patients with known peritoneal carcinomatosis (PC) from colorectal cancer. In: Gastrointestinal Cancers Symposium. 2007
26. Quenet F, Claus C, Roca L, et al. Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from digestive tract cancer-new management with oxaliplatin plus irinotecan: a feasibility study in 37 patients. In ASCO Annual Meeting. 2008
27. Padhani AR, Ollivier L. The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. Br J Radiol 2001;74:983-6